Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA) has received a consensus broker rating score of 1.00 (Strong Buy) from the three analysts that cover the company, Zacks Investment Research reports. Three analysts have rated the stock with a strong buy rating.

Brokerages have set a one year consensus price target of $35.00 for the company and are expecting that the company will post ($0.50) EPS for the current quarter, according to Zacks. Zacks has also assigned Kiniksa Pharmaceuticals an industry rank of 103 out of 255 based on the ratings given to related companies.

A number of analysts recently commented on KNSA shares. JPMorgan Chase & Co. started coverage on Kiniksa Pharmaceuticals in a research report on Monday, June 18th. They set an “overweight” rating and a $29.00 price target for the company. Wedbush started coverage on Kiniksa Pharmaceuticals in a research report on Monday, June 18th. They set an “outperform” rating and a $31.00 price target for the company. JMP Securities increased their price target on Kiniksa Pharmaceuticals from $33.00 to $44.00 and gave the company an “outperform” rating in a research report on Monday, September 17th. Finally, Goldman Sachs Group started coverage on Kiniksa Pharmaceuticals in a research report on Monday, June 18th. They set a “neutral” rating for the company.

Shares of KNSA traded down $1.16 on Tuesday, reaching $29.77. 1,272,422 shares of the company’s stock traded hands, compared to its average volume of 168,404. Kiniksa Pharmaceuticals has a 52-week low of $13.04 and a 52-week high of $32.88.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last issued its quarterly earnings results on Monday, August 6th. The company reported ($0.97) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.44) by ($0.53). equities research analysts predict that Kiniksa Pharmaceuticals will post -2.63 EPS for the current year.

A number of large investors have recently added to or reduced their stakes in the business. Cubist Systematic Strategies LLC bought a new stake in Kiniksa Pharmaceuticals during the second quarter worth about $115,000. BlackRock Inc. purchased a new stake in shares of Kiniksa Pharmaceuticals in the 2nd quarter worth $173,000. Quantitative Systematic Strategies LLC purchased a new stake in shares of Kiniksa Pharmaceuticals in the 2nd quarter worth $348,000. Alps Advisors Inc. purchased a new stake in shares of Kiniksa Pharmaceuticals in the 2nd quarter worth $371,000. Finally, Dean Capital Investments Management LLC purchased a new stake in shares of Kiniksa Pharmaceuticals in the 2nd quarter worth $535,000. 34.91% of the stock is owned by institutional investors and hedge funds.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on the discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its clinical-stage product candidates include Rilonacept, which is in Phase II clinical trials for the treatment of recurrent pericarditis, a debilitating inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; and KPL-716, a monoclonal antibody, which is in Phase 1a/1b clinical trial for the treatment of prurigo nodularis and atopic dermatitis.

Featured Article: Tariff

Get a free copy of the Zacks research report on Kiniksa Pharmaceuticals (KNSA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Kiniksa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiniksa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.